PMID- 29573118
OWN - NLM
STAT- MEDLINE
DCOM- 20190114
LR  - 20190114
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 20
IP  - 8
DP  - 2018 Aug
TI  - SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A 
      systematic review and meta-analysis.
PG  - 1977-1982
LID - 10.1111/dom.13295 [doi]
AB  - The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on risk of 
      stroke have not been conclusively established. Therefore, we conducted a 
      meta-analysis to evaluate the effects of SGLT2 inhibitors on stroke risk in 
      patients with type 2 diabetes mellitus (T2DM) by searching available randomized 
      trials in PubMed, Embase, CENTRAL, Web of Science, Scopus and ClinicalTrials.gov 
      databases. We identified 32 eligible trials involving 75 540 participants. The 
      incidence of stroke in groups receiving SGLT2 inhibitor monotherapy or 
      combination therapy did not differ significantly from that in control groups, 
      with a relative risk (RR) of 1.01 and 1.0, respectively. Three SGLT2 inhibitors 
      were tested, with similar RR values (canagliflozin [RR, 0.91], dapagliflozin [RR, 
      0.99] and empagliflozin [RR, 1.03]). Subgroup analyses showed that RR values were 
      not affected by gender, age, diabetes duration, BMI or HbA1C levels, but Black 
      patients had a lower incidence of stroke than White or Asian patients. This 
      meta-analysis indicated that SGLT2 inhibitor therapy did not increase stroke 
      incidence, and no significant differences in stroke risk were observed among 3 
      SGLT2 inhibitors (class effect). However, the small racial disparity requires 
      further study and confirmation.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Guo, Man
AU  - Guo M
AUID- ORCID: 0000-0001-7646-669X
AD  - Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest 
      Medical University, Luzhou, China.
FAU - Ding, Jingya
AU  - Ding J
AD  - Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest 
      Medical University, Luzhou, China.
FAU - Li, Jingsong
AU  - Li J
AD  - Department of Radiology, Affiliated Hospital of Southwest Medical University, 
      Luzhou, China.
FAU - Wang, Jiying
AU  - Wang J
AD  - Department of Endocrinology, Guangyuan Central Hospital, Guangyuan, China.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest 
      Medical University, Luzhou, China.
FAU - Liu, Cuiping
AU  - Liu C
AD  - Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest 
      Medical University, Luzhou, China.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest 
      Medical University, Luzhou, China.
FAU - Long, Yang
AU  - Long Y
AD  - Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest 
      Medical University, Luzhou, China.
FAU - Gao, Chenlin
AU  - Gao C
AD  - Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest 
      Medical University, Luzhou, China.
FAU - Xu, Yong
AU  - Xu Y
AD  - Department of Diabetes and Endocrinology, Affiliated Hospital of Southwest 
      Medical University, Luzhou, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20180416
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/ethnology
MH  - Diabetic Angiopathies/chemically induced/complications/epidemiology/*prevention & 
      control
MH  - Drug Monitoring
MH  - Drug Therapy, Combination/adverse effects
MH  - Health Status Disparities
MH  - Humans
MH  - Incidence
MH  - Randomized Controlled Trials as Topic
MH  - Risk
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects/*therapeutic use
MH  - Stroke/chemically induced/epidemiology/ethnology/*prevention & control
OTO - NOTNLM
OT  - SGLT2 inhibitor
OT  - diabetes mellitus
OT  - meta-analysis
OT  - stroke
EDAT- 2018/03/25 06:00
MHDA- 2019/01/15 06:00
CRDT- 2018/03/25 06:00
PHST- 2017/12/20 00:00 [received]
PHST- 2018/03/09 00:00 [revised]
PHST- 2018/03/15 00:00 [accepted]
PHST- 2018/03/25 06:00 [pubmed]
PHST- 2019/01/15 06:00 [medline]
PHST- 2018/03/25 06:00 [entrez]
AID - 10.1111/dom.13295 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2018 Aug;20(8):1977-1982. doi: 10.1111/dom.13295. Epub 2018 
      Apr 16.